Why the study?
Does the specific activity of 18F-rhPSMA-7.3 affect its normal-organ and tumor uptake in patients with prostate cancer?
Does the specific activity of 18F-rhPSMA-7.3 affect its normal-organ and tumor uptake in patients with prostate cancer?
A 10-fold decrease in specific activity of 18F-rhPSMA-7.3 has only minor effects on biodistribution, supporting its central production and shipping to PET clinics.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Beamis et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: